Paul Kohlhaas is the co‑founder and CEO of BIO Protocol (also referred to as Bio Protocol/Bio.xyz), a co‑founder and senior leader at Molecule, and a founding steward of VitaDAO. His work focuses on building platforms and governance models to fund and manage biomedical research through decentralized organizations and tokenized intellectual property structures. He studied Economics and International Affairs at the University of St. Gallen between 2012 and 2015. ^{[1] [2]}​

Education

Kohlhaas attended the University of St. Gallen (Universität St. Gallen) from 2012 to 2015, where sources state he studied economics and international affairs/politics. The same body of reporting broadly frames his formal training in economics and policy as a backdrop to later work on incentive design and governance for decentralized research ecosystems. Specific degree distinctions or additional academic affiliations are not consistently detailed across sources used in this entry. ^{[2] [3]}

Career

Kohlhaas’s career spans legal and finance‑adjacent roles, early blockchain business development, and the founding of organizations central to the DeSci movement.

• Early professional experience: A profile in PANews notes he worked in the private equity practice at White & Case LLP in Frankfurt, focusing on private equity transactions and cross‑border M&A, before moving into blockchain roles. It also associates him with subsequent experience at ConsenSys and uPort, reflecting an early shift toward Ethereum‑based identity and infrastructure efforts. The dates for these positions are not specified in the cited sources. ^[4]
• Molecule: Kohlhaas co‑founded Molecule and has been listed at different times as CEO, Chairman & Chief Architect, and Founder & Chairman, reflecting evolving responsibilities as the organization matured. Molecule describes itself as a decentralized biotech protocol and marketplace that connects academics and biotech companies with funding and supports community governance and ownership of research‑related IP. Public org listings and company materials identify him as a leading figure in the project. ^{[5] [6]}
• BIO Protocol (Bio.xyz): By 2025, reporting identifies Kohlhaas as co‑founder and CEO of BIO Protocol, an “AI‑native” decentralized science platform for biotech funding and drug discovery. BIO Protocol has been presented as a spin‑out and evolution of infrastructure intended to link bioDAOs, researchers, and on‑chain capital into a shared “science finance” stack. ^{[1] [7]}
• VitaDAO: Sources also identify Kohlhaas as a founding steward of VitaDAO, a decentralized organization focused on community‑funded longevity and life‑sciences research, where he contributed to the early governance and DeSci narrative linking patient communities, researchers, and funders. ^[2]

Molecule

Molecule is described as a decentralized biotech protocol and marketplace designed to help research teams and institutions finance and govern intellectual property using web3 tooling. Materials associated with the organization present it as a bridge between academia and industry that can structure funding and downstream commercialization through community stewardship and tokenization models. Within public org listings, Kohlhaas is shown as a founder and senior executive/board‑level leader. Across profiles and interviews, Molecule is often referenced as foundational to subsequent DeSci efforts such as BIO Protocol and the emergence of bioDAOs. ^{[5] [6]}​

Molecule’s positioning emphasizes three recurring ideas: enabling more direct funding paths for biomedical research, applying decentralized governance to align researchers and communities, and creating liquid, composable markets for research‑related IP. The project has been cited widely in DeSci circles, and various public profiles treat it as an anchor organization in the DeSci ecosystem where new bioDAOs and research communities have taken shape. While Molecule materials concentrate on mission and governance concepts, granular technical specifications (e.g., chain‑level architecture, smart contract standards, audits) are outside the scope of the sources cited here. ^[5]​

BIO Protocol (Bio.xyz)

​BIO Protocol, led by Kohlhaas as co‑founder and CEO, is framed as an AI‑native DeSci platform for biotech funding and drug discovery. In September 2025, the project announced a 50 million to scientific funding by that time. ^[7]​

The same announcement quoted Kohlhaas on the project’s motivation: “Science today is locked in institutional black boxes, cut off from the very researchers who birth it and the communities primed to accelerate it. By unifying AI, biotech, and crypto in a decentralized platform, researchers and citizen scientists everywhere can collaborate more efficiently and back promising biotech from its earliest stages, compress R&D timelines by years.” The post also highlighted the launch of “BioAgents” as part of the agentic AI layer, including “Aubrai,” introduced in partnership with VitaDAO and Dr. Aubrey de Grey. ^[7]​

An earlier 2024 event recap described BIO as “on‑chain glue” or “connective tissue” for DeSci—linking research IP, DAO treasuries, and liquidity in ways intended to reduce friction in funding and coordinating biomedical research. That coverage summarized reported ecosystem metrics associated with BIO/Molecule‑linked initiatives since 2022: more than six bioDAOs formed, over 10 million in research funded, and an overall ecosystem market capitalization exceeding $200 million. While presented as context for the development of on‑chain science finance, these figures are project‑reported and should be interpreted accordingly. ^[8]​

VitaDAO and the DeSci Movement

Kohlhaas is widely cited as a founding steward of VitaDAO, one of the most visible bioDAOs focused on longevity science. Public profiles frequently link his work at Molecule and BIO Protocol to VitaDAO’s early activity, framing these efforts as part of a shared trajectory to enable communities to collectively fund, govern, and participate in the value of research. Media coverage often uses VitaDAO’s collaborations and external interest (including examples of corporate participation) to illustrate the practical, translational aims of DeSci. ^{[2] [8]}​

Roles and Titles

Across sources, Kohlhaas’s titles reflect overlapping leadership responsibilities:

• BIO Protocol (Bio.xyz): Co‑Founder and Chief Executive Officer by 2025, including responsibility for public communication on product direction, fundraising, and platform features such as BioAgents. ^{[1] [7]}
• Molecule: Co‑founder with subsequent listings as CEO and as Founder & Chairman/Chairman & Chief Architect, suggesting a progression from operational leadership to board‑level and architectural oversight roles over time. ^{[2] [5]}
• VitaDAO: Founding Steward, denoting early governance and contributor status during the DAO’s formative period. ^[2]

Public org charts and profile pages corroborate his association with Molecule’s leadership. Variations in job titles across sources appear to reflect evolving scope rather than contradiction, but individual start and end dates are not consistently specified in the materials cited here. ^{[6] [5]}​

Notable Projects and Initiatives

• BIO Protocol (Bio.xyz): AI‑native DeSci platform that reported a $6.9 million raise in September 2025 to expand on‑chain fundraising, incentive mechanisms, and agentic AI features. The project highlighted an anchor investment by Maelstrom Fund and introduced BioAgents such as “Aubrai,” developed with VitaDAO and Dr. Aubrey de Grey. ^[7]

• Molecule: A decentralized biotech protocol and marketplace described as enabling community ownership/governance of research‑related IP and facilitating connections between researchers and funders. Often cited as the organizational base from which bioDAOs and further DeSci infrastructure emerged. ^[5]

• Reported ecosystem activity: Event coverage in 2024 attributed to BIO/Molecule‑linked efforts a set of composite metrics since 2022—more than six bioDAOs launched, over $20 million raised into DAO treasuries, more than $10 million in funded research, and an ecosystem market capitalization surpassing $200 million. These are reported program metrics and may require independent validation for financial or on‑chain accounting purposes. ^[8]

• Additional initiatives: Sector reporting has linked Molecule to experiments at the boundary of tokenized research coordination and broader crypto culture. For example, PANews describes “Pump.Science,” presented as a Molecule‑launched meme‑coin issuance platform on Solana enabling users to trade meme coins linked to drugs and engage in experimental data prediction. This description has appeared in commentary discussing ethical and regulatory questions raised by gamified participation in biomedical R&D markets. ^[4]

Funding and Financial Milestones

The principal funding disclosure in sources tied directly to Kohlhaas’s leadership is the BIO Protocol financing of $6.9 million, announced in September 2025. The announcement characterized the raise as part of a broader push to make the platform “AI‑native” and to scale mechanisms for on‑chain scientific funding and coordination. It also cited a cumulative “over $50 million” in scientific funding directed by the BIO‑affiliated network by that time. Public‑facing posts do not include detailed capitalization tables or on‑chain treasury breakdowns; independent audits or chain explorers would be required for precise verification. ^[7]

Associations and Collaborations

Kohlhaas’s projects are described as working closely with bioDAOs and research communities. Public announcements have named specific collaborators in the context of product features (e.g., the “Aubrai” BioAgent launched with VitaDAO and Dr. Aubrey de Grey). DeSci Berlin coverage also situates BIO and Molecule alongside a growing set of bioDAOs and participants engaged in bringing scientific IP onto chain and accessing liquidity venues. While these accounts illustrate ecosystem alignment, they do not serve as exhaustive partnership lists. ^{[7] [8]}

Recognition and Influence

Industry coverage characterizes Kohlhaas as an early and prominent figure in DeSci. PANews, in a 2024 feature surveying DeSci entrepreneurs, highlights his co‑founding of Molecule and BIO Protocol and notes recurring collaboration with colleagues such as Tyler Golato. The same article points to ongoing activity across crypto‑biotech initiatives, reflecting a portfolio approach to building scientific finance primitives and DAO‑mediated research funding. ^[4]

Selected Quotations

• “Science today is locked in institutional black boxes, cut off from the very researchers who birth it and the communities primed to accelerate it. By unifying AI, biotech, and crypto in a decentralized platform, researchers and citizen scientists everywhere can collaborate more efficiently and back promising biotech from its earliest stages, compress R&D timelines by years.” — Paul Kohlhaas, on the aims of BIO Protocol and Bio V2 (2025). ^[7]
• In public talks during 2024, BIO was framed as “on‑chain glue” for DeSci—connecting bioDAOs, liquidity, and research assets to reduce “science friction” and enable vertically integrated on‑chain R&D. (Paraphrase; theme reported in event recap.) ^[8]

Personal Life and Languages

Public profiles identify Kohlhaas as based in Switzerland and list multiple language proficiencies, including German and English at native/bilingual levels and French and Spanish at professional working proficiency, with elementary proficiency in Burmese. No additional personal details (such as birth date or family background) are provided in the sources used here. ^[3]

Notes on Verification and Additional Reading

• BIO Protocol’s $6.9M raise (September 2025), “Bio V2” features, BioAgents, anchor investor (Maelstrom Fund), and “>$50M directed” funding metric are drawn from a project announcement. Independent validation (e.g., investor disclosures, on‑chain treasury snapshots) is not included in the cited materials. ^[7]

• The DeSci Berlin 2024 recap provides “ecosystem metrics” for the 2022–2024 period (bioDAOs formed, treasury totals, research funding, market capitalization). These are reported figures aggregated in event coverage rather than audited financial statements. ^[8]

• Roots and roles associated with BIO Protocol can also be cross‑referenced against third‑party project directories. ^[9]

• Public listings corroborate founder and leadership roles at Molecule and BIO Protocol and identify Switzerland as Kohlhaas’s base, but they do not comprehensively resolve job title transitions or timelines. ^{[6] [2]}

• A PANews survey article offers additional context about Kohlhaas’s early legal experience and broader project involvement in DeSci. ^[4]

Interviews

Token Engineering in Pharmaceutical Research Models #01

In an interview published on December 3, 2018, on the YouTube channel “BlockchainForScience,” Paul Kohlhaas discusses the application of token engineering and crypto-economic mechanisms within the pharmaceutical sector.

The interview outlines his description of the existing patent system as a structure that grants exclusive rights over intellectual property, which can limit data sharing and collaboration between entities. He associates this structure with high development costs, extended timelines, and low success rates in drug development, as well as limited incentives to disclose unsuccessful research outcomes.

Kohlhaas describes the Molecule protocol as a framework intended to facilitate alternative coordination mechanisms for research and development. The model is based on blockchain infrastructure and incorporates mechanisms such as curation markets and token bonding curves. These mechanisms are presented as methods for allocating capital and signaling perceived value of intellectual property through market participation.

The discussion also includes the use of non-fungible tokens (NFTs) as representations of patents or chemical compounds. Within this framework, ownership of intellectual property may be structured through smart contracts and associated legal entities, such as patent investment trusts. This structure allows for divisible participation and transferability of associated rights.

The interview further addresses the potential role of this model in enabling participation from multiple stakeholder groups, including researchers, investors, and other participants in the research process. It also notes the inclusion of governance structures and regulatory considerations required for implementation within existing legal systems.

Kohlhaas also references practical constraints, including technical design challenges, legal requirements, and the need for coordination with established industry participants. The discussion presents the model as one of several approaches being explored for organizing research funding and intellectual property management in scientific domains. ^[10]

Decentralized Science and Research Infrastructure #02

In a talk published on June 25, 2025, on the Molecule YouTube channel, Paul Kohlhaas discussed developments related to decentralized science (DeSci) and outlined his interpretation of its trajectory. He described the current scientific and biomedical research landscape as structured around established funding systems, patent frameworks, and institutional decision-making processes.

According to Kohlhaas, a large share of researchers’ time is allocated to funding acquisition rather than research activities. He presented this distribution as a structural characteristic of the existing system and drew a comparison to features observed in traditional financial systems, where institutional arrangements influence resource allocation.

Kohlhaas described decentralized science as a model that utilizes blockchain-based infrastructure and Web3 tools to support research funding, coordination, and governance. Within this framework, he referred to the concept of “permissionless science,” in which participation in research-related processes is not limited to centralized entities. He identified tokenized intellectual property and decentralized autonomous organizations (DAOs) as mechanisms associated with this approach.

He also referenced the use of artificial intelligence systems in research workflows, including tools designed to generate and evaluate hypotheses and assist in data analysis. In his description, these systems operate alongside decentralized coordination models.

In summary, Kohlhaas characterized decentralized science as an approach that restructures how research activities, funding, and governance are organized, with reduced reliance on centralized institutions. ^[11]